Mycamine (Micafungin Sodium)

Mycamine (micafungin sodium) is used to treat invasive fungal infections caused by Candida species.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections in adult and pediatric patients.
• Candida esophagitis: promotes healing of esophageal infection in immunocompromised individuals.
• Candida peritonitis: used to manage intra‑abdominal Candida infection in patients with peritoneal contamination.
• Candida febrile neutropenia: administered to febrile neutropenic patients with suspected or proven Candida infection.

• Micafungin sodium belongs to the echinocandin class and inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall formation, the drug leads to osmotic instability and fungal cell death, while having minimal effect on human cells that lack this pathway. The inhibition is concentration‑dependent and results in rapid fungicidal activity against most Candida species.

Micafungin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature.
• Nausea: mild to moderate feeling of sickness.
• Headache: occasional mild headache.
• Elevated liver enzymes: mild increase in ALT/AST.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Hypersensitivity reactions: anaphylaxis or severe skin reactions.
• Hepatotoxicity: significant elevation of liver enzymes or jaundice.
• Renal impairment: acute kidney injury in susceptible patients.
• Hematologic abnormalities: neutropenia or thrombocytopenia.

Before initiating Mycamine therapy, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function: assess baseline kidney function and monitor during treatment.
• Hepatic function: evaluate liver enzymes prior to use and observe for changes.
• Drug interactions: review concomitant medications that may affect liver metabolism.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Allergic history: avoid in patients with known hypersensitivity to echinocandins.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin sodium can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Cyclosporine: increased micafungin exposure may raise toxicity risk.
• Rifampin: strong enzyme induction can markedly reduce micafungin levels.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may alter micafungin metabolism.
• Anticonvulsants (e.g., carbamazepine): potential reduction in drug concentration.
• Immunosuppressants (e.g., tacrolimus): monitor levels due to possible pharmacokinetic changes.